Table 2.
Effect of UDCA on miRNA expression profiles during liver regeneration
| miRNA | UDCA vs. Control | UDCA Sham vs. Control Sham | UDCA PH vs. Control PH | UDCA PH vs. UDCA Sham | Validated Targets |
|---|---|---|---|---|---|
| hsa-miR-106a | 1.52 | VEGFA, RB1, AML1, APP | |||
| hsa-miR-143 | 1.54 | 1.50 | MAPK7, KRAS | ||
| hsa-miR-181d | 2.25 | ||||
| hsa-miR-191 | 1.82 | ||||
| hsa-miR-199b | 0.47 | ||||
| hsa-miR-20a | 1.51 | VEGFA, AML1, E2F1, CCND1 | |||
| hsa-miR-21 | 1.81 | 2.43 | 27 validated targets | ||
| hsa-miR-24 | 1.99 | NOTCH1, p38, p16, ACVR1B, DHFR | |||
| hsa-miR-302d | 2.65 | 3.59 | VEGFA, TRPS1, MBLN2, KLF13 | ||
| hsa-miR-31 | 1.49 | ||||
| hsa-miR-342 | 0.50 | ||||
| hsa-miR-4255p | 2.59 | ||||
| hsa-miR-451 | 0.45 | ABCB1 | |||
| hsa-miR-513 | 1.91 | 1.76 | 2.13 | ||
| hsa-miR-539 | 2.65 | ||||
| hsa-miR-552 | 0.48 | ||||
| hsa-miR-568 | 0.31 | 0.32 | |||
| hsa-miR-594 | 1.80 | ||||
| hsa-miR-603 | 0.41 | ||||
| hsa-miR-620 | 0.45 | ||||
| hsa-miR-638 | 2.90 | ||||
| hsa-miR-7 | 2.45 | PAK1, RAF1, IRS1, IRS2, EGFR | |||
| mmu-miR-362 | 0.50 | ||||
| mmu-miR-451 | 0.42 | ||||
| mmu-miR-674* | 1.74 | ||||
| mmu-miR-685 | 0.50 | ||||
| mmu-miR-691 | 0.35 | ||||
| mmu-miR-708 | 0.26 | ||||
| mmu-miR-720 | 4.94 | ||||
| mmu-miR-744 | 1.53 | ||||
| mmu-miR-760 | 2.04 | 1.90 | |||
| mmu-miR-761 | 0.49 | ||||
| mmu-miR-762 | 1.92 | ||||
| mmu-miR-764 | 0.50 | ||||
| 3p | |||||
| rno-miR-329 | 0.48 | 0.44 | |||
| rno-miR-346 | 1.76 | ||||
| rno-miR-350 | 0.50 | 0.50 | |||
| rno-miR-382* | 0.38 | CAPN8, CNTN4, SEPT3, TAGLN, VIM | |||
| rno-miR-7 | 2.31 |
List of miRNAs differentially expressed at 36 h after PH between ursodeoxycholic acid (UDCA)-fed animals and control diet-fed animals, UDCA-fed Sham animals and control-diet Sham animals, UDCA-fed PH animals and control-diet PH animals, and UDCA-fed PH and Sham animals. Mean expression values were determined following global normalization and statistical analysis as described in materials and methods. ABCB1, ATP-binding cassette, sub-family B (MDR/TAP), member 1; ACVR1B, activin A receptor, type IB; AML1, runt-related transcription factor 1; APP, amyloid precursor protein; CAPN8, calpain 8; CCND1, cyclin D1; CNTN4, contactin 4; DHFR, dihydrofolate reductase; E2F1, E2F transcription factor 1; EGFR, epidermal growth factor receptor; IRS1, insulin receptor substrate 1; IRS2, insulin receptor substrate 2; KLF13, Kruppel-like factor 13; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; MAPK7, mitogen-activated protein kinase 7; MBLN2, muscleblind-like 2; NOTCH1, Notch homolog 1; p16, cyclin-dependent kinase inhibitor 2A; p38, mitogen-activated protein kinase 14; PAK1, p21 protein (Cdc42/Rac)-activated kinase 1; RAF1, v-raf-1 murine leukemia viraloncogene homolog 1; RB1, retinoblastoma 1; SEPT3, septin 3; TAGLN, transgelin; TRPS1, trichorhinophalangeal syndrome I; VEGFA, vascular endothelial growth factor A; VIM, vimentin.